How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Moss evaluates a case that requires CAR-T cell therapy and discusses practical issues hematologists should be aware of during introduction of this treatment.
Dr. Moss covers a radical revision of the classification of dendritic cells and monocytes.
Dr. Moss reviews the first trial to show that an immunotherapeutic agent improves survival over chemotherapy in relapsed or refractory ALL patients.
Dr. Moss reviews the first phase III randomized study in systemic mastocytosis (SM), focusing attention on the unmet need of patients with indolent forms of SM who have refractory mediator symptoms despite the use of conventional medications.
Dr. Moss covers updates in the management of the most common subtype of leukemia, CLL. He focuses on the value of BTK inhibition.
Dr. Moss covers a study that compares the PD-1 inhibitor pembrolizumab with brentuximab vedotin in subjects with relapsed or refractory classical HL.
Dr. Moss looks at updates regarding the genomic classification of and treatment approaches to acute myeloid leukemia.
Dr. Moss looks at three studies that show the success of three triplet combinations for the treatment of relapsed myeloma.
Dr. Moss reviews the often-raised question of how we select a donor for a patient who needs a stem cell transplant and the three main options, which include an HLA-matched unrelated donor (URD), umbilical cord blood transplantation, or a haploidentical donor (HD).
Dr. Moss looks at the role of antithymocyte globulin (ATG) in treating graft-versus-host disease (GVHD).
September-October 2017Volume 14, Issue 5
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology